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Summary  
Background 
There is a great unmet clinical need for efficacious, tolerable, economical and orally 
administrated drugs for the treatment of inflammatory bowel disease (IBD). New 
therapeutic avenues have become possible including the development of medications that 
target specific genetic pathways found to be relevant in other immune mediated diseases.  
Aims 
To provide an overview of recent clinical trials for new generation oral targeted medications 
that may have a future role in IBD management. 
Methods 
Pubmed and Medline searches were performed up to 01/03/18 using keywords: ‘IBD’, ‘UC’, 
‘CD’, ‘inflammatory bowel disease’ ‘ulcerative colitis’, Crohn’s disease’  in combination with 
‘phase’, ‘study’, ‘trial’, and ‘oral’. A manual search of the clinical trial register, article 
reference lists, abstracts from meetings of Digestive Disease Week, United European 




In randomised controlled trials primary efficacy endpoints were met for tofacitinib (JAK 1/3 
inhibitor-phase III), upadacitinib (JAK 1 inhibitor-phase II) and AJM-300 (α4-integrin 
antagonist-phase II) in ulcerative colitis. Ozanimod (S1P receptor agonist-phase II) also 
demonstrated clinical remission. For Crohn’s disease, filgotinib (JAK1 inhibitor-phase II) met 
primary endpoints and laquinimod (quinolone-3-carboxide small molecule-phase II) was also 
efficacious. Trials using mongersen (SMAD7 inhibitor) and vidofludimus (dihydroorotate 
dehydrogenase inhibitor) have been halted.  
Conclusions 
This is potentially the start of an exciting new era in which multiple therapeutic options are 
at the disposal of physicians to treat IBD on an individualised basis. Head-to-head studies 
with existing treatments and longer term safety data are needed for this to be possible.  
Keywords 
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INTRODUCTION 
Inflammatory bowel disease (IBD) is a chronic and progressive immune mediated condition 
of the gastrointestinal (GI) tract influenced by both genetic and environmental factors. 
Often patients require lifelong medical therapy and others surgery depending on disease 
severity. A meta-analysis showed the 5 and 10 year risk for needing surgery for Crohn’s 
disease (CD) and ulcerative colitis (UC) was 33.3%, 46.6%, 11.6 and 15.6% respectively (1). 
Approximately 25% of CD patients will require additional intestinal surgery within five years 
of their first (2). The risk of requiring surgery after diagnosis has decreased over the past six 
decades but remains a significant burden (3).  This has both financial implications and a 
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negative impact on a patient’s quality of life (4). For a considerable duration, the mainstay 
of medical treatment for IBD has been the use of steroids for the induction of remission and 
immunomodulatory drugs such as azathioprine, mercaptopurine and methotrexate to 
maintain remission (5). However, since 1997 when Targan et al reported the first 
randomised controlled trial (RCT) to show the effectiveness of the anti-tumour necrosis 
factor (TNF) infliximab, there has been a paradigm shift in IBD management. This has led to 
the introduction of a number of anti-TNF and other biological agents such as adalimumab, 
certolizumab, golimumab, ustekinumab and vedolizumab (6-15).  
During the course of this disease, many patients are treated with various 
immunosuppressive medications either due to a lack of efficacy, loss of response or drug 
intolerance (16). Up to a third of patients treated with anti-TNF therapy are primary non-
responders, whilst a significant proportion (10-15% per year) lose response due to antibody 
formation (immunogenicity failure) (7, 17-19). These biological agents are also associated 
with significant adverse events, such as opportunistic infections and immune complications 
(20, 21). Furthermore, these drugs have the added inconvenience of parenteral 
administration and associated heavy health care costs (22). In a climate where hospital 
room capacity is limited, the use of novel oral medication could potentially increase capacity 
and reduce costs associated with drug infusions.  
There remains a great unmet clinical need for new efficacious, tolerable, economical and 
orally administrated drugs. As our understanding of the major inflammatory pathways in 
IBD have evolved, multiple new therapeutic avenues have become possible. These include 
the development of new oral medications that target specific pathways found to be relevant 
in other immune mediated diseases. These include inhibition of cytokine cell signalling, 
lymphocyte influx and mast cell activity, as well as promotion of the activity of inherent 
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immunosuppressive pathways (23). This review provides an overview of recent clinical trials 
for new generation oral targeted medications that may have a role in IBD management in 
the future.  
METHODOLOGY 
A broad electronic literature search was conducted using Pubmed and Medline up to 1st 
March 2018 to identify the relevant studies. The following keywords were used ‘IBD’, ‘UC’, 
‘CD’, ‘inflammatory bowel disease’ ‘ulcerative colitis’, Crohn’s disease’,  in combination with 
‘phase’, ‘study’, ‘trial’, and ‘oral’. A manual search of the reference list of initially selected 
articles, abstracts from the yearly meetings of Digestive Disease Week, United European 
Gastroenterology Week and European Crohn’s and Colitis congress up to 1st March 2018 was 
also conducted. Clinical trial status was checked on http://www.clinicaltrials.gov and 
http://www.clinicaltrialsregister.eu. Only articles published in English were reviewed.  
 
POTENTIAL NEW TREATMENTS: ULCERATIVE COLITIS 
 
α4-INTEGRIN ANTAGONIST  
Integrins comprise a family of α4β heterodimeric transmembrane receptors that are 
constitutively expressed on leukocyte surfaces and are activated by pro-inflammatory 
cytokines released by activated T cells (24). The integrin family consists of at least 24 
different forms representing the combination of 18 α subunits and 8 β subunits. The α-
subunit determines integrin ligand specificity. The β subunit connects to the cytoskeleton 
and affects multiple signalling pathways (25). Inhibiting the interactions between adhesion 
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molecules and lymphocyte integrins has already proved to be a successful therapeutic 
strategy for the management of IBD (26).  
Vedolizumab is a recombinant humanized, anti-α4β7 integrin monoclonal antibody, which 
has shown efficacy for induction and remission in both UC and CD (14, 27). Natalizumab 
(Biogen Idec, Massachusetts, United States) an anti-a4 integrin antibody is also effective in 
IBD (28, 29) and etrolizumab (Roche, Basel, Switzerland) an anti-b7 integrin antibody was 
investigated in a phase II trial which showed this was more likely to lead to clinical remission 
than placebo in UC (30). Phase III trials are currently being evaluated in IBD (31-33). A more 
recent development is AJM 300 (Ajinomoto Pharmaceuticals, Tokyo, Japan), an oral α4-
integrin antagonist that acts by inhibiting the binding of lymphocyte integrins to adhesion 
molecules expressed on inflamed intestinal endothelium (34). The gut specific α4β7 integrin 
is expressed on lymphocytes in the gut-associated lymphoid tissue, and interacts with 
mucosal addressin cell adhesion molecule 1 (MAdCAM-1), whilst the non-gut specific α4β1 
integrin is expressed on most leukocytes and interacts with vascular cell adhesion molecule 
1 (VCAM1) (35). 
AJM-300 was evaluated in a multicentre, randomised, double-blind, placebo-controlled, 
phase II clinical study (36), involving 102 patients with moderately active UC (Mayo scores of 
6-10, endoscopic subscores ≥2, and rectal bleeding subscores ≥1) and an inadequate 
response or intolerable side effects to aminosalicylates or corticosteroids. 960mg dose or 
placebo was used three times a day for 8 weeks. The primary end-point was a clinical 
response (decrease in Mayo Score ≥3 points and a decrease of ≥30% from baseline, with a 
decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of 0 or 
1) at 8 weeks. Secondary endpoint was clinical remission (Mayo Clinic score of ≤2 and no 
subscore >1 and mucosal healing). The latter was defined as endoscopic subscore of ≤1. 
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AJM-300 was more effective than placebo in delivering clinical response, remission and 
mucosal healing. Clinical response were 62.7% in AJM-300 group compared to 25.5% in the 
placebo group, (odds ratio [OR] 5.35; 95% confidence interval [CI]: 2.23-12.82; p= 0 .0002). 
Clinical remission rates were 23.5% in the AJM300 group and 3.9% in the placebo group (OR 
7.81; 95% CI: 1.64-37.24; p=0 .0099).  Mucosal healing rates were 58.8% in AJM300 group 
and 29.4% in placebo group (OR 4.65; 95% CI: 1.81-11.90; p=0 .0014) (36).  
AJM300 was well tolerated, with no severe adverse events observed in this treated cohort. 
Non-significant laboratory test abnormalities were observed in the AJM300 group. One of 
the most concerning adverse events of α4 integrin blockade is the development of 
progressive multifocal leukoencephalopathy (PML), which is seen in higher frequency in 
patients treated with the natalizumab (37). No PML cases were observed in this study 
though the safety follow-up period in this study was only short-term (36). However, 
development opportunities for alpha 4 integrin blockers are likely to be limited due to this   
risk. 
 A phase III study is planned.  
 
SPHINGOSINE RECEPTOR MODULATOR 
Sphingosine 1-phosphate (S1P) is a sphingosine-derived circulating phospholipid that binds 
to five G-protein-coupled receptors (GPCRs), termed S1P1-5 (38). S1P receptor’s function to 
regulate processes such as migration, adhesion and endocytosis. They also mediate 
angiogenesis, vascular permeability and trafficking lymphocytes (39, 40). Ozanimod 
(RPC1063; Celgene, New Jersey, USA) is an oral sphingosine receptor agonist under 
development for the treatment of UC and multiple sclerosis. Ozanimod stimulation of 
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S1P1 on lymphocytes results in receptor internalization and a functional antagonism that 
causes sequestration of lymphocytes in peripheral lymphoid organs and reduction in 
circulating lymphocytes. In addition, the activation of S1P receptors on endothelial cells 
tightens the endothelial barrier, further restricting T cell movement into the intestine (41).  
Ozanimod was evaluated in a randomised, double-blind, placebo-controlled phase II trial the 
TOUCHSTONE study (42). 197 patients with moderate-to-severe active UC (Mayo score ≥6 
and endoscopy subscore ≥2) were randomised in approximately 1:1:1 fashion to once daily 
1 mg ozanimod (n=67), 0.5 mg ozanimod (n=65) or placebo (n=65) for 8 weeks (the 
induction phase). The primary endpoint was clinical remission (defined as Mayo score ≤2 
and no subscore > 1) at week 8. The exploratory secondary end points were clinical 
response (defined as reduction in Mayo score of ≥3 points and ≥30% from baseline, with a 
decrease in the rectal bleeding score of ≥1 or a rectal bleeding score ≤1) at week 8. Mucosal 
healing (defined as endoscopy subscore ≤1) and other objective markers such as CRP and 
faecal calprotectin were measured to examine for changes from baseline. Clinical remission 
was slightly higher in the 1mg group when compared to placebo (16% vs 6%, p=0.048). 
There was no significant difference in the proportion of patients with a clinical response or 
endoscopic mucosal healing. Ninety one patients completed a 32 week double blind 
maintenance phase but there was no significant difference between clinical remission, 
response and mucosal healing. Ozanimod did not show an adequate efficacy signal and the 
follow up period was too short to fully assess drug safety. Adverse events were comparable 
in the three groups; one patient developed a sinus bradycardia and first degree AV block 
leading to discontinuation of the drug and four patients had elevated liver enzymes (42). 
The long-term follow up of patients involved in the TOUCHSTONE study demonstrated 
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treatment with ozanimod to be safe, efficacious and well tolerated in patients with 
moderate-to-severe UC followed up to two years (43).  
Initial results of a further phase II trial of 69 patients treated with ozanimod for moderate-
to-severe CD demonstrated a clinical improvement by week 4 and endoscopic improvement 
by week 12 (44, 45). A phase III trial in moderate-to-severe UC (46) and a phase III trial 
assessing efficacy and safety in UC (47) are currently ongoing.  
Etrasimod (APD334; Arena Pharmaceuticals, California, United States) is a similar compound 
which selectively targets S1P1, S1P4 and S1P5 in in-vitro assays thus also has the potential 
for immune cell modulation (48). Etrasimod is currently been evaluated in a randomised, 
parallel phase II study in patients with UC (49, 50). Another S1P receptor target that has 
completed a phase II study is amiselimod (MT-1303; Mitsubishi Tanabe Pharma Corporation, 
Osaka, Japan) in CD (51). However, the development of amiselimod has recently been 
discontinued.  
 
PHOSPHODIESTERASE 4 INHIBITOR 
Phosphodiesterase 4 (PDE4) is an enzyme responsible for lysis of cyclic adenosine 
monophosphate (cAMP) in inflammatory cells.  Apremilast (CC-10004, Celgene, New Jersey, 
USA) is an oral small-molecule inhibitor of PDE4 modulating pro- and anti-inflammatory 
mediators (52).  A phase II randomised, double-blind, placebo-controlled study to evaluate 
the efficacy and safety of apremilast has recently completed recruitment. 170 patients with 
active UC (Mayo score ≥6 to ≤11, Mayo endoscopic score of ≥2) who have previously failed 
conventional treatment but were biologic naïve were recruited. Patients were randomised 
to 60mg/day, 80mg/day or placebo for 12 weeks. The primary endpoint was the proportion 
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of patients in clinical remission (Mayo score ≤2 and no subscore > 1) at 12 weeks. The 
secondary endpoint was the proportion of patients with clinical response (reduction in 
Mayo score of ≥3 points and ≥30% from baseline, with a decrease in the rectal bleeding 
score of ≥1 or a rectal bleeding score ≤1) at 12 weeks.  
A significant number of patients treated with 60mg/day were in clinical remission when 
compared to placebo (31.6% vs 13.8%, p≤0.05). Clinical response was significantly higher in 
the 80mg/day group when compared with placebo (67.3% vs 46.6%, p≤0.05). In the 12 week 
follow up, the 60mg/day dose showed the most efficacy when compared with placebo. 
There were no new safety reports (53). This phase II study is currently still active: patients 
will receive a further 40 weeks of treatment with either 60mg/day or 80mg/day of 
apremilast and be followed up to week 52 (54).  
 
MAPK INHIBITORS  
Mitogen-activated protein kinase (MAPK) superfamily plays an essential role in eukaryotic 
cell regulation to produce pro-inflammatory cytokines. P38α, JNKs and ERK1/2 have been 
shown to be significantly activated in the inflamed colonic mucosa of IBD patients (55).  
RDP58 (SangStat Medical Corporation, California, USA), also known as delmitide acetate, is a 
drug that disrupts cell signalling which is responsible for activating p38 MAPK, JNK, and I 
kappa kinase (IKK) (56). Travis et al first evaluated the efficacy, safety and tolerability of 
RDP58 in a phase II trial (57). Data for two studies was reported for patients with mild-to-
moderate UC (Simple Colitis Activity Index (SCCAI) score 4 to 9 and active disease at 
sigmoidoscopy (Baron Score≥ 1) within this trial. In the first study, 34 patients were 
10 
 
randomised (2:1) to RDP58 100mg or placebo. In the second study, 93 patients were 
randomised (1:1:1) to receive RDP58 200mg, RDP 300mg or placebo.  
No statistical difference was observed in the primary and secondary endpoints between 
RDP58 100mg and placebo. In the second study, treatment success was higher with 
increasing doses: 71% and 72% for the 200mg and the 300mg dose respectively when 
compared to 43% for placebo (p = 0.016). Adverse events were similar between RDP58 
300mg and placebo (57). No further clinical trials evaluating RDP58 in UC are planned. 
 
MODIFIED RELEASE PHOSPHATIDYCHOLINE  
UC patients have been found to have a low intrinsic phosphatidylcholine content that 
reduces intestinal mucus barrier function, making it more susceptible to inflammation and 
ulceration (58, 59). An improved, modified release phosphatidylcholine (LT02; Dr. Falk 
Pharma GmbH, Freiburg, Germany) and the first oral therapy targeting stabilisation of gut 
barrier was evaluated in a double blinded, randomised, placebo controlled phase II study. 
156 UC patients with an inadequate response to mesalazine, SCCAI ≥ 5 and bloody diarrhoea 
were treated with placebo, 0.8, 1.6 or 3.2 g of phosphatidylcholine. The primary endpoint 
was defined as a >3 point drop in SCCAI from baseline to the end of treatment. SCCAI score 
change for placebo, 0.8g, 1.6g and 3.2g was 33.3%, 44.3% and 51.7% respectively. The 3.2g 
dose was statistically superior when compared to placebo at 51.7% compared to 33.3% 
(p=0.03). Histological remission for placebo and all phosphatidylcholine doses was 20% 
compared to 40.5% (p=0.016). Phosphatidylcholine was found to be safe (60). However, two 
phase III trials have since been terminated in 2017 (61, 62): the first trial because it 
appeared not to induce remission with the reason for termination of the second trial not yet 
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disclosed. Another phase III trial is still ongoing comparing phosphatidylcholine to placebo 
and mesalazine for maintenance of remission in UC (63). 
 
OTHER ORAL AGENTS CURRENTLY IN EARLY DEVELOPMENTAL STAGE 
Free fatty acids (FFA) act as energy source but also important for metabolic and 
inflammation regulation. FFA2 receptor and other G protein receptors are activated by FFA. 
Knockout mice studies suggest FFA2 has important roles in controlling inflammation (64). 
GLPG0974 (Galapagos NV, Mechelen, Belgium) is a selective antagonist of  FFA2 and was 
shown to be safe and tolerable in healthy subjects (65). A randomised, exploratory, double 
blind, phase II trial evaluating the safety, tolerability, efficacy, pharmacokinetics and 
pharmacodynamics of GLPG0974 in UC has been completed and results are awaited (66).  
There are many other potential new agents at varying stage of developments. LYC-30937 
(Lycera Corp, Minnesota, United States) is an oral ATPase modulator currently in phase II 
studies evaluating its use in UC (67, 68). TOP-1288 (Topivert Pharma Ltd, London, England) is 
a nonselective kinase inhibitor that has recently been evaluated in a rectal solution in UC 
(69) and now an oral administered phase I study on healthy subjects has recently been 
completed (70). GSK2982772 (GlaxoSmithKline, Brentford, England)  is a  RIP1 kinase 
inhibitor currently being evaluated in a phase II study (71). Rosiglitazone (GlaxoSmithKline, 
Brentford, England) a PPAR-γ agonist has been shown to be efficacious in mild to moderate 
ulcerative colitis in a phase II trial (72). A randomised, cross over placebo controlled phase II 
trial of VB-201 (VBL Therapeutics, Tel Aviv, Israel), a small oxidized phospholipid molecule in 
UC has recently been completed but as this study did not meet its primary endpoints there 
are no plans to continue drug development (73). Finally, AVX-470 (Avaxia Biologics, 
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Massachusetts, United States) is an orally administered anti-TNF agent that seems 
promising after the completion of a phase I study (74).  
 
POTENTIAL NEW TREATMENTS: CROHN’S DISEASE 
 
QUINOLONE-3 CARBOXIDE 
Laquinimod (TV-5600; Teva Pharmaceutical Industries Ltd, Petah Tikva, Israel) is an oral 
quinolone-3-carboxide small molecule that has shown efficacy in treating multiple sclerosis 
(MS) (75, 76) and may have a potential role in treating Huntington’s disease (77) and  lupus 
nephritis (78). Both animal and in vitro experimental studies have alluded to various 
mechanisms by which this drug interacts with the immune and nervous system in MS. 
Laquinimod has been shown to decrease pro-inflammatory immune cells and the activation 
of anti-inflammatory genes. It also exhibits effects on regulatory T cells by promoting their 
differentiation (79). A study in experimental autoimmune encephalomyelitis (EAE) (an 
animal model of MS) has found that quinolone-3-carboxamides inhibited the interaction of 
S100A9 with two receptors, toll-like receptor 4 and receptor of advanced glycation end 
products, thereby preventing the downstream release of inflammatory cytokines, including 
tumour necrosis factor α (TNFα) and interleukin (IL)-1 (80). Laquinimod has also been shown 
to increase levels of the anti-inflammatory cytokines IL-10 and transform growth factor β 
(TGFβ) in both T and B cells, suppressing immune activity and downregulating the 
immunogenicity of the dendritic cell response (81). Laquinimod treatment has been shown 
to inhibit the ability of the CCR7-binding chemokine, CCL21, to stimulate very late antigen-4 
(VLA-4) adhesiveness to its natural ligand, vascular cell adhesion molecule-1 (VCAM-1) in 
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splenic T cells isolated from immunized mice (82) and reduce the in vitro secretion of several 
chemokines participating in the recruitment of leucocytes to inflammatory tissue sites (83). 
Laquinimod was evaluated in an exploratory phase IIa multicentre, randomised, double 
blind placebo-controlled and dose-finding trial. 117 patients were randomised to 
laquinimod doses of 0.5, 1, 1.5 or 2 mg/day, in a 1:1:1:1 fashion, while 63 patients were 
exposed to placebo for 8 weeks. CDAI scores, CRP, and faecal calprotectin were recorded at 
week 0, 2, 6, 8 and 12. Treatment failures (TF) were defined as patients who were not 
responding, needed biologic, immunosuppressive therapy or surgery. Clinical remission was 
defined as (CDAI <150 and no TF). Endpoints were to assess safety profile, dosing and the 
number of patients in clinical remission (CDAI <150 and no TF). Other endpoints included 
the number of patients with a clinical response with a reduction of CDAI score by ≥70 & 
≥100 points from baseline, in remission, no TF and a mean change in objective markers from 
baseline. Although this study was not powered for efficacy, the lowest dose 0.5mg/day had 
the highest response rate when compared to placebo. 48% were in remission at the end of 
week 8 compared to 15.9% in the pooled placebo group. CDAI 70 and 100 were 62% and 
55% respectively in the 0.5mg/day group compared with 35% and 32% respectively of 
patients exposed to placebo. The higher doses showed similar responses to placebo (84). 
D'Haens et al also investigated whether changes in plasma concentrations could explain the 
clinical improvement seen in lower doses. Laquinimod concentration reached its maximum 
within one hour of administration and remained at a steady plasma concentration 
throughout the 24 hour period. The pharmacokinetics seems to be linear in CD patients in 
the dose range 0.5-2mg/day. The pharmacokinetics could not explain the improved 
response at lower dose (85). 
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Laquinimod could be used safely for 8 weeks at all doses with an adverse event profile 
similar to placebo. Incidence of adverse events in all doses was 86.2%-96.7% vs placebo 
82.5% (84, 85).  
Phase IIb/III trials are currently awaited. 
 
ANTISENSE OLIGONUCLEOTIDE SMAD7 INHIBITOR  
Reduced tissue growth factor-β receptor type I (TGF-β1) cytokine activity due to 
overexpression of SMAD7 is seen in individuals with IBD (86, 87). Mongersen (GED-0301; 
Celgene, New Jersey, USA) is a new class of drug (86) which acts to reinstate the TGFβ1 
immunosuppressive pathway (88). 
Mongersen’s efficacy and safety was evaluated in a multicentre, randomised, double-blind, 
placebo-controlled phase II trial involving 166 patients with moderate-to-severe CD (Crohn’s 
Disease Activity Index 220-400). Participants were randomised to receive placebo or daily 
mongersen for 14 days.  Clinical response was significantly higher in the 160mg and 
40mg/day groups when compared to placebo (65% and 55% vs 10%, p<0.001 (89). A post-
hoc analysis of this trial showed neither an elevated CRP nor duration of disease impacted 
on efficacy. No association was seen between baseline CDAI and remission rates but the 
40mg dose showed the lowest remission rates with CDAI ≥260 (90).  
However, a significant limitation of the Monteleone et al study was that the inclusion 
criteria were based on CDAI score and with no objective endoscopic measure of disease 
activity. At baseline, 39% of participants had a normal CRP (91) implying low disease activity 
in the exposed population, so patients were not reflective of the usual moderate-to-severe 
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patients.  Moreover the primary endpoint was clinical remission only as measured through 
CDAI and this was only measured at 28 days. As such, no data are available on long-term 
clinical remission, endoscopic remission or safety.  
In a recent noteworthy turn of events, Celgene has recently terminated their Phase III 
REVOLVE and SUSTAIN clinical trials of mongersen following recommendation from the 
external Data Monitoring Committee. This decision was based upon the lack of emerging 
benefit but not safety findings during their recent review of interim unblinded data. The 
planned Phase III DEFINE study in Crohn’s will also not be initiated. However, a phase II trial 
in UC has recently completed recruitment (92). Celgene is waiting to review the full dataset 
from this trial for UC to determine the next steps. 
 
POTENTIAL NEW TREATMENTS: CROHN’S DISEASE AND ULCERATIVE COLITIS 
 
JANUS KINASE INHIBITORS 
Janus kinases (JAKs) are a family of intracellular protein tyrosine kinases: JAK1, JAK2, JAK3 
and tyrosine kinase 2 (TYK2). These are crucial to the downstream regulation of 
inflammatory mediators.  Transcription factor STATs (signal transducer and activation of 
transcription) are activated by the binding of transmembrane receptors. A number of 
cytokines deliver their function by activating the JAK-STAT pathway thus having an 
important role in the immune system and development of immune mediated disorders (93, 
94).  JAK inhibition results in suppression of B and T cells but retains regulatory T cell 




Tofacitinib (CP-690,550; Pfizer, New York City, USA) is a JAK 1 and 3 inhibitor that has been 
studied in autoimmune conditions, including rheumatoid arthritis and psoriasis with a good 
overall efficacy and an acceptable safety profile (97-99).  
The use of tofacitinib in UC was evaluated in a multi-centre, double-blind, placebo-
controlled, dose-ranging phase II study, including 194 adults with moderate-to-severe active 
UC (Mayo score ≥ 6 and endoscopic subscore ≥ 2) who had failed conventional therapy 
(100). Stable doses of mesalamine or prednisolone at a maximum of 30mg were permitted 
during the trial period. Patients were randomised to tofacitinib 0.5, 3, 10, or 15 mg or 
placebo twice daily for 8 weeks. The primary efficacy end point was a clinical response, 
defined as an absolute decrease in Mayo score of  ≥ 3 points and relative decrease  ≥30%, 
with an accompanying decrease in the rectal bleeding subscore of  ≥ 1 point or an absolute 
rectal bleeding subscore of 0 or 1. Of the secondary end points, clinical remission was 
defined as Mayo score ≤2 with no individual subscore >1 at week 8, endoscopic response 
was defined as a decrease from baseline in the subscore ≥1 at week 8, and endoscopic 
remission was defined as endoscopy subscore of 0 at week 8. The only statistical significant 
clinical response was with the 15mg twice a day dose when compared to placebo (78% vs 
42%, p<0.001). Clinical remission was 13%, 33%, 48%, and 41% at 0.5mg (p=0.76), 3mg p= 
0.01), 10 mg (p<0.001), and 15 mg (p<0.001), respectively when compared with 10% for 
placebo. Tofacitinib was well tolerated and reasonably effective in moderate-to-severe UC 
(100). Tofacitinib is also associated with dose-dependent improvement in health related 
quality of life measures (101). Faecal calprotectin showed a moderate correlation with 
clinical and endoscopic outcomes in patients receiving tofacitinib. A cut off value of 150 
mg/kg showed a fair to good accuracy in classifying these outcomes (102). 
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Sandborn et al recently reported the use of tofacitinib as induction and maintenance 
therapy in UC. A number of randomised, double blind, placebo controlled phase III trials 
were conducted.  The OCTAVE Induction 1 and 2 trials included patients with moderate-to-
severe UC (Mayo score ≥6, endoscopic subscore ≥ 2 and rectal bleeding subscore ≥ 2). 
Patients with previous treatment failures or unacceptable side effects to anti-TNF or 
immunomodulatory drugs were included in these studies. Concomitant medications 
included prednisolone <25mg/day and oral aminosalicylates. In the first two trials, 598 and 
541 patients were randomised (4:1) to induction therapy (10mg twice a day) or placebo for 
8 weeks. Primary endpoint of clinical remission (a total Mayo score of ≤2, with no subscore 
>1 and a rectal bleeding subscore of 0) at 8 weeks was 18.5% in tofacitinib group versus 
8.2% in the placebo (p=0.007) in the OCTAVE 1 trial. In the OCTAVE 2 trial this was 16.6% 
versus 3.6% (p<0.001). In the OCTAVE 1 trial, the 10mg group mucosal healing rate was 
31.3% compared to placebo 15.6% (p<0.001). In the OCTAVE 2 trial, this was 28.4% vs 11.6% 
(p<0.001).  
Patients who achieved a clinical response (reduction total Mayo score ≥3 points, rectal 
bleeding score ≥1 or absolute rectal bleeding subscore of 0 or 1) in the OCTAVE 1 and 2 
were eligible to participate in the third OCTAVE Sustain trial. Patients were randomised 
(1:1:1) to receive 5mg, 10mg or placebo twice a day for 52 weeks. The primary endpoint was 
remission at 52 weeks. Secondary endpoints were mucosal healing at 52 weeks and 
sustained steroid free remission (both at 24 and 52 weeks). In this trial clinical remission at 
52 weeks were 34.3% in 5mg group, 40.6% in the 10mg group compared with 11.1% in the 
placebo (p<0.001 for both comparisons). Mucosal healing occurred in significantly more 
patients at 52 weeks. In the 5mg, 10mg and placebo this was 37.4%, 45.7% and 13.1% 
(p<0.001) respectively. Sustained steroid free remission was 34.4%, 47.3% and 5.1% 
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(p<0.001) in the 5mg, 10mg and placebo group respectively. These results demonstrate that 
tofacitnib is more effective as an induction and maintenance agent than placebo (103). The 
3 year interim efficacy and safety data from the OCTAVE 1, 2 and OCTAVE Sustain studies 
open label long-term extension study reported a similar safety profile to those observed 
with rheumatoid arthritis patients and a sustained efficacy with 5mg and 10mg twice a day 
dose (104). Currently one phase I trial (105) and a phase III trial (106) are underway for 
tofacitnib in UC.   
However in patients with CD tofacitinib did not exhibit a significant clinical remission and 
response rate. The use of tofacitinib in CD was evaluated in a multi-centre, double-blind, 
placebo-controlled, phase II trial including 139 patients with moderate–to-severe CD (CDAI 
220-450). Patients were randomised to (1, 5 or 15 mg twice a day) or placebo for 4 weeks. 
The primary and secondary endpoints were the proportion of clinical responders at week 4 
(CDAI of ≥70 points) and clinical remission at 4 weeks (CDAI <150) respectively. There was 
no significant difference in the primary and secondary endpoints. It is unclear whether these 
findings are due to the high placebo response rate or difference in the immunopathology CD 
and UC (107). Panés et al reported a recently conducted phase IIb trial in which CD patients 
were randomised to 5 mg (n=86), 10 mg twice (n=86) or placebo (n=91) twice a day for 8 
weeks. There was no significant difference in remission rates reported despite the longer 
treatment duration. The clinical response was slightly significantly higher as was CRP 
reduction in the tofacitinib group when compared to placebo. There was no change in in 
faecal calprotectin levels (108).  Panés et al later reported on two randomised, double-blind, 
placebo-controlled, multicentre phase IIb studies of 180 patients with moderate–to-severe 
CD. Clinical remission was not significantly different to placebo although there were minor 
treatment benefits seen in change in biomarkers (secondary endpoints) (109). A number of 
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factors may have contributed to the high response rate seen in placebo patients. Endoscopy 
was not centrally read and the severity and extent of ulceration was not defined despite 
been part of the inclusion criteria. There was also no baseline threshold for objective 
markers of disease activity. Variation in endoscopic ulceration and inflammatory markers at 
baseline may have influence the treatment effect of drugs (109, 110). 
The most commonly reported adverse events were influenza and nasopharyngitis. 
Neutropenia has also been reported as well as serious infections such as abscess and 
pneumonia. There was also a dose-dependent increase in low-density lipoprotein (LDL) and 
high-density lipoprotein (HDL) cholesterol which is not completely understood (87, 100, 
107).  
Filgotinib 
Filgotinib (GLPG0634; Galapagos NV, Mechelen, Belgium) is an oral JAK1 inhibitor. Vermeire 
et al evaluated its efficacy and safety in moderate-to-severe CD (CDAI 220-450) with 
histological evidence of active inflammation in a randomised, double-blind, placebo-
controlled phase II study. 174 patients were randomised (3:1) to filgotinib 200 mg once a 
day or placebo for 10 weeks. Patients were then assigned according to their CDAI clinical 
responder status to filgotinib 100mg, 200mg or placebo once a day for a further 10 weeks. 
The primary endpoint was clinical remission (CDAI ≤150) at 10 weeks. Secondary endpoints 
included clinical remission at weeks other than week 10; endoscopic response and clinical 
response (change from baseline in overall CDAI score and in CDAI component subscores). 
Clinical response was achieved in 59% in the filgotinib group compared to 41% in placebo 
(p=0.453). Clinical remission was 47% compared to 23% in placebo (p=0.077). The safety 
profile was satisfactory and clinical remission was induced in the filgotinib group. Response 
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rate was almost twofold higher in patients naïve to anti-TNFs compared to those exposed to 
at least one. The data suggest that filgotinib could be effective in both anti-TNF naïve and 
exposed (111). A recent post hoc analysis of this phase II study showed that clinical 
remission is still seen in CD regardless of disease location and duration (112). Currently 
phase III trials are underway in CD and UC (113-116).  
Upadacitinib 
Sanborn et al evaluated the safety and efficacy of a JAK 1 inhibitor upadacitinib (ABT-494; 
AbbVie, Illinois, United States) in CD patients who had inadequate response or intolerant of 
immunomodulators or anti- TNF therapy in a phase II, multicentre, randomised, double 
blind placebo controlled trial. This trial included 220 patients with moderate–to-severe CD 
(CDAI 220-450). Patients were randomised to upadaciitinib 3, 6, 12, 24mg twice a day, 24mg 
once a day or placebo for 16 weeks. Concomitant steroid use was allowed and tapered from 
week 2. The primary endpoints were clinical remission at week 16 (stool frequency (SF) ≤1.5 
or abdominal pain (AP) ≤1, and both no worst from baseline) and endoscopic remission at 
week 12/16 (Simplified Endoscopic Score (SEC) for CD ≤4 and ≥2 point reduction from 
baseline, no subscore >1). The overall dose response relationship was also investigated. 
Significantly more patients achieved clinical remission with 6mg twice a day dose when 
compared with placebo (27% vs 11% p≤0.05). There was a significant dose relationship for 
endoscopic remission when  doses 12mg, 24mg twice a day and 24mg once a day compared 
to placebo (8% p≤0.05 , 22%  p≤0.001, 14% p≤0.01 and 0% respectively). This study 
demonstrated both clinical and endoscopic benefit with 6mg doses and above (117, 118). 
Upadacitinib use also results in a significant and sustainable reduction in markers of 





A number of JAK inhibitors are currently in the development phase. A Phase IIb multi-centre 
randomised, double blind, placebo controlled, parallel group, dose response trial evaluating 
the safety and efficacy of peficitinib (ASP015K; Astellas Pharma, Tokyo, Japan), a non-
selective JAK inhibitor in moderate-to-severe active UC, has recently been completed (121). 
TD-1473 (Theravance Biopharma, San Francisco, US) a non-selective JAK inhibitor is 
currently been evaluated in a phase I trial in patients with moderate-to-severe UC (122).  
 
DIHYDROOROTATE DEHYDROGENASE INHIBITOR 
Vidofludimus (4SC AG, Martinsried, Germany) is a small molecule which acts by inhibiting 
activated B and T cells by blocking dihydroorotate dehydrogenase (123). It also inhibits pro-
inflammatory cytokines. Herrlinger et al conducted a 12 week open label study to evaluate 
the efficacy, tolerability and safety of vidofludimus in maintaining remission in 34 steroid 
dependent IBD patients. Despite being relatively safe and well tolerated a further 
developmental phase II study was discontinued by 4SC in October 2016.(124).  
Figure 1, table 1 and 2 summarise molecular targets and drug trial results.  
 
CONCLUSION 
For UC, significant treatment benefits have been seen with AJM-300, tofacitinib, and 
upadacitinib. Ozanimod showed some treatment benefit but the majority of endpoints were 
not statistically significant. All agents have a favourable short-term safety profile, with the 
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exception of risk of development of PML with the α4 integrin blockade of AJM-300. Phase III 
trials are either being planned or are underway for each to gain more data.  
For CD, treatment benefits were seen with laquinimod, and phase III trials are underway.  
However, there is no apparent benefit with tofacitinib treatment, although the short study 
duration may have impacted on this. Although the phase II study of filgotinib did not shown 
any statistically significant benefit, phase III studies for both CD and UC are currently active.  
Successful phase II but failed phase III trials, such as the mongersen trial, may have been 
due to high placebo response rates which are unpredictable. This could potentially be 
largely rectified by introducing endoscopy disease activity in the entry criteria and the use of 
patient reported outcomes (PRO) as outcome measures of efficacy rather than the older 
disease activity indices. Failed phase III after successful phase II is not very common but 
some examples of previous failed therapy were the Anti-IL17A cytokine therapy which was 
likely due to a mechanistic failure and IL10 due to dosing and drug delivery (125, 126).  
Other weakness with a number of the CD trials is that they do not assess mucosal healing at 
endoscopy which is a desirable treatment goal that leads to increased rates of clinical 
remission, reduced hospitalization and surgery rates (127). Other weaknesses include low 
CRP at inclusion, no centrally read endoscopy, short follow up period and a lack of forced 
steroid tapering dosage. Rectifying these weaknesses is likely to give a true reflection of the 
difference between the trial agents and placebo, therefore, potentially enabling better 
design and success at phase III.  
Novel oral targeted therapies offer exciting new avenues of treatment for IBD by targeting 
different parts of the inflammatory cascade. However, for targeted therapy to be 
achievable, a better understanding of the mechanisms leading to disease development is 
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crucial. A combination of increased genetic information and biomarker development is 
required to achieve this.  New oral therapies have the potential to provide a more 
acceptable, convenient treatment on an individualised basis. This may allow for the 
introduction of more targeted immunosuppression thus reducing inflammation, disease 
progression and associated complications which ultimately lead to an improved quality of 
life. Moreover, a better understanding of the disease pathogenesis might allow a strategy to 
combine targeted therapies hence ultimately achieving the holy grail of truly personalising 
therapies in IBD. 
However, long term infection and malignancy rates also need to be better determined in 
large prospective studies in addition to side effects, hospital admission rates and other 
significant costs. There is a growing need for long phase IV studies for these drugs in 
development and the use of registries like TREAT and PIANO to assess the long-term safety 
of these drugs. Potentially, the development of more targeted therapies may also mean that 
complications can be avoided in susceptible individuals compared to the current blanket 
approach to treatment.  
At present, the majority of IBD patients respond to some form of current therapy but the 
loss of response is a problem. Although population-based studies are suggesting a decrease 
in surgical rates for both CD and UC (3, 128), better and more targeted therapies are needed 
to sustain this paradigm shift world-wide.  There is presently no head-to-head comparison 
between presently licenced therapies and future targeted therapies to allow a better 




Moreover, there are no clear predictive biomarkers to identify the subgroups of IBD patients 
that will respond to these new targeted therapies. If these agents are successful, then this 
will lead to an exciting new era of personalised and precise therapy in IBD, as is already the 
case in other areas of medicine. 
 
 
Figure 1: Summary of oral drugs and targets 
Drug mechanisms and cellular targets.  T= T lymphocytes, DC=Dendritic cells, IL-Interleukin, TGFβ= Tissue 









Table 1: Summary of trials in ulcerative colitis 
Drug trial Clinical response* Clinical remission** Summary and safety 
Tofacitinib  




 Placebo 42% 
 0.5 mg 32% 
 3 mg 48%  
 10 mg 61% 
 15 mg 78% 
(p<0.001) 
 Placebo 10% 
 0.5 mg 13% (p=0.76) 
 3 mg 33% (p=0.01) 
 10 mg 48% (p<0.001) 
 15 mg 41% (p<0.001) 
Dose-related treatment benefit with 





 Placebo 25.5% 
 960 mg tds 62.7% 
(p=0.0002) 
 Placebo 3.9% 
 960 mg tds 23.5% 
(p=0.0099) 
Significant treatment benefit with no 
severe adverse events 
Ozanimod 
S1P receptor agonist 
N= 197 
Phase II 
 Placebo 37% 
 0.5 mg 54% 
 1.0 mg 57% 
p=ns 
 Placebo 6% 
 0.5 mg 14% 
 1.0 mg 16% (p=0.048). 
Dose-related treatment benefit with 
no severe adverse effects. Mild 







 Placebo 46.7% 
 60mg/day 61.4% 
 80mg/day 67.3% 
(p≤0.05) 
 Placebo 13.8% 
 60mg/day 31.6% (p≤0.05) 
 80mg/day 21.8% 
Treatment benefit at 12 weeks with no 






 Placebo 60% 
 0.8g/day 77.5% 
 1.6g/day 73.2% 
 3.2g/day 82.9% 
(p=0.03) 
 Placebo 15% 
 0.8g/day 27.5% 
 1.6g/day 22% 
 3.2g/day 31.4% (p=0.09) 
Improvement in disease activity and 
acceptable safety  
Two phase 3 studies have been 




*Clinical response: absolute decrease in Mayo score of  ≥ 3 points and relative decrease  ≥30%, with an 
accompanying decrease in the rectal bleeding subscore of  ≥ 1 point or an absolute rectal bleeding subscore of 
0 or 1, at week 8.LT-02: SCCAI decrease ≥ 2.  
**Clinical remission: Mayo score ≤2 with no individual subscore >1 at week 8. LT-02: < 3 mean SCCAI and 
“blood in stool” subscore of 0.  
























Table 2: Summary of trials in Crohn’s Disease 







 Placebo 31.7%   
 0.5 mg/day 55.2% 
 1.0 mg/day 40% 
 1.5 mg/day 27.6% 
 2.0 mg/day 27.6% 
p=ns 
 Placebo 15.9% 
 0.5 mg/day 48.3% 
 1.0 mg/day 26.7% 
 1.5 mg/day  13.8% 
 2.0 mg/day 17.2% 
p=ns 
Treatment benefit seen for 0.5mg dose, with 






 Placebo 41% 
 200mg/day 59% 
(p=0·0453)  
 Placebo 23% 
 200mg/day 47% 
(p=0·0077) 






  Placebo 32% *** 
 12mg/day 57% 
p≤0.01 
 48mg/day 61% 
p≤0.01 
 Placebo 11% **** 
 
 12mg/day 27% 
 
p≤0.05 
Induces remission in CD in doses 12mg/day 







 Placebo 17% 
 10 mg/day 37% 
(p=0.04) 
 40 mg/day 58% 
(p<0.001) 
 160 mg/day 72% 
(p<0.001) 
 Placebo 10% 
 10mg/day 12% 
 40mg/day 55% 
 160mg/day 65% 
(p<0.001) 
Significant dose-related treatment benefit 
that is sustained, with safety profile similar 
to placebo. 
Phase 3 studies have been discontinued 
Phase II trial in UC completed recruitment 
*Clinical response: reduction of CDAI by >100 points by day 28. Filgotimib: change from baseline in overall CDAI 
score and in CDAI component subscores.  
** Clinical remission: reduction of CDAI by >150 after 2 week and maintained for > 2 week. Filgotimib trial used 
CDAI ≤150 at 10 weeks.  
28 
 
***Clinical response (_30% reduction from baseline in AP or SF with neither worse than baseline) 
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